SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of report (date of earliest event reported):
August 29, 2017
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified in
(State or Other Jurisdiction
509 Madison Avenue, Suite 306, New York, New
(Address of principal executive offices)
Registrant’s telephone number, including
area code: (212) 980-9155
Copy of correspondence to:
Marc J. Ross, Esq.
James M. Turner, Esq.
Sichenzia Ross Ference Kesner LLP
1185 Avenue of the Americas, 37th
New York, New York 10036
Tel: (212) 930-9700 Fax: (212) 930-9725
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On August 29, 2017, Tonix Pharmaceuticals Holding
Corp. (the “Company”) presented two posters entitled “Phase 2 Trial of a Low Dose, Bedtime, Proprietary,
Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) for the Treatment of Military-Related PTSD: Mediators and Moderators of
Treatment Response” (the “First Poster”) and “Efficacy and Safety of a Low Dose, Bedtime,
Proprietary, Sublingual Formulation of Cyclobenzaprine (TNX-102 SL*) for the Treatment of Military-Related PTSD: Study Protocol
of a Phase 3 Randomized Placebo-Controlled Trial (P301)” (the “Second Poster” and with the First Poster,
the “Posters”), at the 2017 Military Health System Research Symposium in Kissimmee, Florida (the “MHSRS”).
* TNX 102 SL is an investigational new drug
and has not been approved for any indication
The foregoing description of the Posters is
qualified in its entirety by reference to each of the Posters, a copy of each of which is filed as Exhibit 99.1 and
Exhibit 99.2, respectively, to, and each is incorporated by reference in, this Current Report.
On August 29, 2017, the Company issued a press
release announcing the Poster presentation at the MHSRS. A copy of the press release that discusses this matter is filed as Exhibit
99.3 to, and incorporated by reference in, this Current Report.
The information in this Current Report is being
furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or
otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference
into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth
by specific reference in any such filing.
|Item 9.01||Financial Statements and Exhibits.|
** Furnished herewith.
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
TONIX PHARMACEUTICALS HOLDING CORP.
|Date: August 29, 2017
||By: /s/ BRADLEY SAENGER|
||Chief Financial Officer|